Abstract
We measured the sero-positivity rate of serum α-fetoprotein (αFP) of gastric cancer patients by ELISA assay; forty-two curatively resected patients, 14 palliatively resected patients, 8 who received explo-laparotomy or bypass surgery and 18 patients with systemic metastasis. The sero-positive rate was 9.8% (8/82) and the positivity increased with cancer progression. Sex, age and pathological type were similar between αFP-positive and - negative patients. The overall synchronous hepatic metastasis rates in αFP- positive and αFP-negative groups were 37.5% (3/8) and 12.2% (9/74), respectively (p=0.08). The predictability of synchronous liver metastasis in eight αFP-positive patients were as follows: 37.5% of total patients (3/8), 50.0% (3/6) of unresectable patients, and 60.0% (3/5) of patients with systemic metastasis. In three αFP-positive patient with liver metastasis, all the hepatic lesions were intrahepatic and multiple, while in αFP- negative patients, 67% (6/9) of the hepatic lesions was single intrahepatic lesion or surface nodule. The predictability of both synchronous and metachronous liver metastasis in αFP-positive gastric cancer patients was 75%. These findings suggested that, in advanced stomach cancer patients, especially in stage IV, αFP can be used in predicting liver metastasis during follow-up.
| Original language | English |
|---|---|
| Pages (from-to) | 1179-1184 |
| Number of pages | 6 |
| Journal | Oncology Reports |
| Volume | 5 |
| Issue number | 5 |
| Publication status | Published - 1998 Aug 24 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Alpha-fetoprotein-producing gastric cancer. / Lee, Ruth; Rha, Sun Young; Ahn, Joong Bae; Shim, Kwang Yong; Choi, Jin Hyuk; Young Lim, H. O.; Yoo, Nae Choon; Noh, Sung Hoon; Kim, Joo Hang; Roh, Jae Kyung; Min, Jin Sik; Kim, Byung Soo; Chung, Hyun Cheol.
In: Oncology Reports, Vol. 5, No. 5, 24.08.1998, p. 1179-1184.Research output: Contribution to journal › Article
TY - JOUR
T1 - Alpha-fetoprotein-producing gastric cancer
AU - Lee, Ruth
AU - Rha, Sun Young
AU - Ahn, Joong Bae
AU - Shim, Kwang Yong
AU - Choi, Jin Hyuk
AU - Young Lim, H. O.
AU - Yoo, Nae Choon
AU - Noh, Sung Hoon
AU - Kim, Joo Hang
AU - Roh, Jae Kyung
AU - Min, Jin Sik
AU - Kim, Byung Soo
AU - Chung, Hyun Cheol
PY - 1998/8/24
Y1 - 1998/8/24
N2 - We measured the sero-positivity rate of serum α-fetoprotein (αFP) of gastric cancer patients by ELISA assay; forty-two curatively resected patients, 14 palliatively resected patients, 8 who received explo-laparotomy or bypass surgery and 18 patients with systemic metastasis. The sero-positive rate was 9.8% (8/82) and the positivity increased with cancer progression. Sex, age and pathological type were similar between αFP-positive and - negative patients. The overall synchronous hepatic metastasis rates in αFP- positive and αFP-negative groups were 37.5% (3/8) and 12.2% (9/74), respectively (p=0.08). The predictability of synchronous liver metastasis in eight αFP-positive patients were as follows: 37.5% of total patients (3/8), 50.0% (3/6) of unresectable patients, and 60.0% (3/5) of patients with systemic metastasis. In three αFP-positive patient with liver metastasis, all the hepatic lesions were intrahepatic and multiple, while in αFP- negative patients, 67% (6/9) of the hepatic lesions was single intrahepatic lesion or surface nodule. The predictability of both synchronous and metachronous liver metastasis in αFP-positive gastric cancer patients was 75%. These findings suggested that, in advanced stomach cancer patients, especially in stage IV, αFP can be used in predicting liver metastasis during follow-up.
AB - We measured the sero-positivity rate of serum α-fetoprotein (αFP) of gastric cancer patients by ELISA assay; forty-two curatively resected patients, 14 palliatively resected patients, 8 who received explo-laparotomy or bypass surgery and 18 patients with systemic metastasis. The sero-positive rate was 9.8% (8/82) and the positivity increased with cancer progression. Sex, age and pathological type were similar between αFP-positive and - negative patients. The overall synchronous hepatic metastasis rates in αFP- positive and αFP-negative groups were 37.5% (3/8) and 12.2% (9/74), respectively (p=0.08). The predictability of synchronous liver metastasis in eight αFP-positive patients were as follows: 37.5% of total patients (3/8), 50.0% (3/6) of unresectable patients, and 60.0% (3/5) of patients with systemic metastasis. In three αFP-positive patient with liver metastasis, all the hepatic lesions were intrahepatic and multiple, while in αFP- negative patients, 67% (6/9) of the hepatic lesions was single intrahepatic lesion or surface nodule. The predictability of both synchronous and metachronous liver metastasis in αFP-positive gastric cancer patients was 75%. These findings suggested that, in advanced stomach cancer patients, especially in stage IV, αFP can be used in predicting liver metastasis during follow-up.
UR - http://www.scopus.com/inward/record.url?scp=13144276272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13144276272&partnerID=8YFLogxK
M3 - Article
C2 - 9683831
AN - SCOPUS:13144276272
VL - 5
SP - 1179
EP - 1184
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 5
ER -